Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patients to be treated with radiotherapy

Next Previous
Trial Profile

A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patients to be treated with radiotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms RT-Immune

    • Most Recent Events

    • 27 Sep 2018 Planned End Date changed from 1 Apr 2021 to 31 Jul 2021.
    • 27 Sep 2018 Planned primary completion date changed from 1 Jul 2020 to 31 Jul 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top